Patents by Inventor Marcus Conrad

Marcus Conrad has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Spiropyrazine derivatives as inhibitors of non-apoptotic regulated cell-death
    Patent number: 10647687
    Abstract: The present invention relates to spiropyrazine compounds which are inhibitors of non-apoptotic regulated cell death, and to pharmaceutical compositions containing such compounds. Furthermore, the present invention relates to the use of such compounds and pharmaceutical compositions in therapy, in particular in the treatment of a condition, disorder or disease that is characterised by non-apoptotic regulated cell-death or where non-apoptotic regulated cell-death is likely to play or plays a substantial role.
    Type: Grant
    Filed: November 10, 2015
    Date of Patent: May 12, 2020
    Assignee: Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH)
    Inventors: Marcus Conrad, Joel Schick, Bettina Proneth, Peter Sennhenn
  • Spiroquinoxaline derivatives as inhibitors of non-apoptotic regulated cell-death
    Patent number: 10280179
    Abstract: The present invention relates to compounds which are inhibitors of non-apoptotic regulated cell death, and to pharmaceutical compositions containing such compounds. Furthermore, the present invention relates to the use of such compounds and pharmaceutical compositions in therapy, in particular in the treatment of a condition, disorder or disease that is characterized by non-apoptotic regulated cell-death or where non-apoptotic regulated cell-death is likely to play or plays a substantial role.
    Type: Grant
    Filed: September 18, 2017
    Date of Patent: May 7, 2019
    Assignee: HELMHOLTZ ZENTRUM MÜNCHEN DEUTSCHES FORSCHUNGZENTRUM FÜR GESUNDHEIT UND UMWELT (GMBH)
    Inventors: Marcus Conrad, Joel Schick, Bettina Proneth, Peter Sennhenn
  • SPIROPYRAZINE DERIVATIVES AS INHIBITORS OF NON-APOPTOTIC REGULATED CELL-DEATH
    Publication number: 20180362475
    Abstract: The present invention relates to spiropyrazine compounds which are inhibitors of non-apoptotic regulated cell death, and to pharmaceutical compositions containing such compounds. Furthermore, the present invention relates to the use of such compounds and pharmaceutical compositions in therapy, in particular in the treatment of a condition, disorder or disease that is characterised by non-apoptotic regulated cell-death or where non-apoptotic regulated cell-death is likely to play or plays a substantial role.
    Type: Application
    Filed: November 10, 2015
    Publication date: December 20, 2018
    Inventors: Marcus Conrad, Joel Schick, Bettina Proneth, Peter Sennhenn
  • SPIROQUINOXALINE DERIVATIVES AS INHIBITORS OF NON-APOPTOTIC REGULATED CELL-DEATH
    Publication number: 20180065982
    Abstract: The present invention relates to compounds which are inhibitors of non-apoptotic regulated cell death, and to pharmaceutical compositions containing such compounds. Furthermore, the present invention relates to the use of such compounds and pharmaceutical compositions in therapy, in particular in the treatment of a condition, disorder or disease that is characterised by non-apoptotic regulated cell-death or where non-apoptotic regulated cell-death is likely to play or plays a substantial role.
    Type: Application
    Filed: September 18, 2017
    Publication date: March 8, 2018
    Inventors: Marcus Conrad, Joel Schick, Bettina Proneth, Peter Sennhenn
  • Spiroquinoxaline derivatives as inhibitors of non-apoptotic regulated cell-death
    Patent number: 9802956
    Abstract: The present invention relates to compounds which are inhibitors of non-apoptotic regulated cell death, and to pharmaceutical compositions containing such compounds. Furthermore, the present invention relates to the use of such compounds and pharmaceutical compositions in therapy, in particular in the treatment of a condition, disorder or disease that is characterised by non-apoptotic regulated cell-death or where non-apoptotic regulated cell-death is likely to play or plays a substantial role.
    Type: Grant
    Filed: July 15, 2014
    Date of Patent: October 31, 2017
    Assignee: Helmholtz Zentrum Munchen-Deutsches Forschungszentrum fur Gesundheit und Umwelt (GmbH)
    Inventors: Marcus Conrad, Joel Schick, Bettina Proneth, Peter Sennhenn
  • SPIROQUINOXALINE DERIVATIVES AS INHIBITORS OF NON-APOPTOTIC REGULATED CELL-DEATH
    Publication number: 20160222025
    Abstract: The present invention relates to compounds which are inhibitors of non-apoptotic regulated cell death, and to pharmaceutical compositions containing such compounds. Furthermore, the present invention relates to the use of such compounds and pharmaceutical compositions in therapy, in particular in the treatment of a condition, disorder or disease that is characterised by non-apoptotic regulated cell-death or where non-apoptotic regulated cell-death is likely to play or plays a substantial role.
    Type: Application
    Filed: July 15, 2014
    Publication date: August 4, 2016
    Inventors: Marcus CONRAD, Joel SCHICK, Bettina PRONETH, Peter SENNHENN
  • Novel form of the PHGPx protein as a diagnostic marker for male infertility
    Publication number: 20040219562
    Abstract: This invention relates to a novel form of the PHGPx protein, the sperm nuclei glutathione peroxidase (snGPx) as well as portions thereof playing a role in mammalian spermatogenesis, and to the nucleic acids encoding the same. The invention further relates to vectors containing said nucleic acid and to host cells transformed by these vectors. Furthermore the invention comprises antibodies specific for the above proteins/peptides as well as the use of the proteins/peptides in the diagnosis or therapy of male infertility.
    Type: Application
    Filed: August 7, 2003
    Publication date: November 4, 2004
    Inventors: Dietrich Behne, Georg Bornkamm, Markus Brielmeier, Henning Pfeifer, Antonios Kyriakopoulos, Marcus Conrad, Jorg Schmidt
  • Spiroquinoxaline derivatives as inhibitors of non-apoptotic regulated cell-death
    Patent number: RE48992
    Abstract: The present invention relates to compounds which are inhibitors of non-apoptotic regulated cell death, and to pharmaceutical compositions containing such compounds. Furthermore, the present invention relates to the use of such compounds and pharmaceutical compositions in therapy, in particular in the treatment of a condition, disorder or disease that is characterised by non-apoptotic regulated cell-death or where non-apoptotic regulated cell-death is likely to play or plays a substantial role.
    Type: Grant
    Filed: October 31, 2019
    Date of Patent: March 29, 2022
    Assignee: Helmholtz Zentrum München-Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH)
    Inventors: Marcus Conrad, Joel Schick, Bettina Proneth, Peter Sennhenn